Patient Assessment Protocol Comprehensive medical history with obesity-specific screening Physical examination including BMI, waist circumference, and body composition analysis Laboratory workup: complete metabolic panel, lipid panel, HbA1c, thyroid function, insulin levels Screening for sleep apnea, PCOS, Cushing syndrome, and other secondary causes of obesity Mental health screening for binge eating disorder and depression Readiness-to-change assessment Medication Formulary for Your Medical Weight Loss Program GLP-1 receptor agonists: Semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Zepbound) Sympathomimetic agents: Phentermine (short-term), phentermine/topiramate (Qsymia) Other FDA-approved options: Naltrexone/bupropion (Contrave), orlistat (Xenical/Alli) Off-label considerations: Metformin, topiramate, bupropion (when clinically appropriate and properly documented) Your medical weight loss program's protocols should specify prescribing criteria, dosing escalation schedules, monitoring requirements, and discontinuation criteria for each medication
Apply evenly across the face and neck
It will require well planned studies that account for weight and glycemic changes in order to firmly distinguish these pathways
Catch colorectal cancer early Most colorectal cancer starts as a growth, or polyp, in the colon or rectum
GH release starts within minutes, but noticeable benefits such as better sleep, higher energy, or improved body composition may take 412 weeks of steady use
This is part of Wegovys FDA-approved prescribing guidelines: WEGOVY delays gastric emptying
